Saving orphans: BRAF targeting of histiocytosis

Blood. 2013 Feb 28;121(9):1487-8. doi: 10.1182/blood-2013-01-475962.

Abstract

In this issue of Blood, Haroche and colleagues report significant therapeutic activity of the BRAF inhibitor, vemurafenib, in 3 patients with rare histiocytic conditions, Erdheim-Chester disease and Langerhans cell histiocytosis.

Publication types

  • Comment

MeSH terms

  • Erdheim-Chester Disease / drug therapy*
  • Female
  • Histiocytosis, Langerhans-Cell / drug therapy*
  • Humans
  • Indoles / therapeutic use*
  • Male
  • Proto-Oncogene Proteins B-raf / genetics*
  • Sulfonamides / therapeutic use*
  • Vemurafenib

Substances

  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf